Cardiol Therapeutics, Inc., is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease.
Cardiol Therapeutics, Inc. has clinical studies in progress for the potential treatment of Recurrent Pericarditis (MAvERIC Study) and Acute Myocarditis (Archer Trial), as well as developing a drug formulation intended for use in Heart Failure. Heart Failure is a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.
Please read the full article below which documents marked reductions in pericarditis pain and inflammation with the administration of CardiolRx.
